6 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 9 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Recruiting 2, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Laekna Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors LAE118, Fulvestrant, Palbociclib - Patients With Advanced Solid Tumors | Phase 1 | Not yet recruiting | Laekna Limited | 150 | 2026-08-01 | 2026-08-26 |
| A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants LAE103 injection, LAE102 injection in combined with LAE103 injection, Saline - Overweight and Obesity | Phase 1 | Recruiting | Laekna Limited | 104 | 2025-12-30 | 2026-09-21 |
| A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women LAE102 SC, Placebo SC, LAE102 IV - Postmenopausal, Healthy Adult Female Participants | Phase 1 | Completed | Laekna Limited | 32 | 2025-04-22 | 2025-11-17 |
| Evaluate LAE102 in Healthy and Overweight/Obese Subjects LAE102 intravenous administration, placebo intravenous administration, LAE102 subcutaneous administration - Overweight and Obese Volunteers | Phase 1 | Recruiting | Laekna Limited | 160 | 2024-06-25 | 2026-01-09 |
| Human Mass Balance and Biotransformation Study of [14C]Afuresertib [14C]Afuresertib - Healthy Volunteer | Phase 1 | Completed | Laekna Limited | 6 | 2022-08-06 | 2023-05-15 |
| Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 Afuresertib, Nab paclitaxel, Docetaxel - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Completed | Laekna Limited | 22 | 2022-07-01 | 2025-11-17 |
| Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Afuresertib, Afuresertib/placebo - Breast Cancer | Phase 3 | Active not recruiting | Laekna Limited | 256 | 2022-02-18 | 2026-04-02 |
| PhI to Solid Tumors and PhII to Locally Advanced or mTNBC LAE005 + Afuresertib + Nab-Paclitaxel - Solid Tumor, TNBC - Triple-Negative Breast Cancer | Phase 1 | Completed | Laekna Limited | 21 | 2021-06-12 | 2024-10-10 |
| Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian Paclitaxel, Afuresertib - Platinum-resistant Ovarian Cancer | Phase 2 | Completed | Laekna Limited | 150 | 2020-07-07 | 2026-10-19 |
| Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Phase I and Phase II: LAE001/prednisone + afuresertib - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Completed | Laekna Limited | 49 | 2019-09-13 | 2024-10-10 |
| A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer LAE001 - Prostate Cancer Metastatic | Phase 1 / Phase 2 | Terminated | Laekna Limited | 33 | 2019-04-05 | 2025-09-10 |
Overweight (2) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Obesity (1) · Prostatic Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
afuresertib (5) · Fulvestrant (2) · 130-nm albumin-bound paclitaxel (1) · Clinical Trials, Phase I as Topic (1) · Docetaxel (1) · Paclitaxel (1) · Prednisone (1) · Sodium Chloride (1) · Taxes (1) · palbociclib (1) · sintilimab (1)
China (8) · United States (4) · Australia (1) · South Korea (1)
Binghe NA Xu (1) · Dingwei Ye, MD (1) · Dr. Hugh Coleman, MD (1) · Herzog Thomas, Professor (1) · Lin Shen, Director (1) · Liyan Miao (1) · Wenyue Ma (1) · Xuening Li, Professor (1) · Yong Yue, MD (1)